EUA
LumiraDx SARS-CoV-2 Ag Test
FDA Emergency Use Authorization · LumiraDx UK Ltd. (an indirect, wholly owned subsidiary of Roche) · Jun 10, 2025
Key facts
| Product | LumiraDx SARS-CoV-2 Ag Test |
|---|---|
| Company | LumiraDx UK Ltd. (an indirect, wholly owned subsidiary of Roche) |
| Product type | Microfluidic Immunofluorescence Assay, Instrument Read, Serial Screening, Single Target |
| Date | Jun 10, 2025 |
| FDA page | fda.gov |
At a glance
- 1–9 Authorization documents
- 1–9 EUAs for this company
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Emergency Use Authorizations
Emergency Use Authorizations allow the FDA to permit unapproved medical products, or unapproved uses of approved products, during a declared public health emergency.
Source: U.S. Food and Drug Administration (FDA), Emergency Use Authorizations · Source date: